0.6981

0.51% -0.0036

After Hours: .72 0.0219 +3.14%

Gossamer Bio Inc (GOSS)

Overview News Price History Option Chain Financials Discussions Forecast

Gossamer Bio Inc stock is traded at $0.6981, with a volume of 517.43K. It is down -0.51% in the last 24 hours and down -23.65% over the past month. Gossamer Bio Inc is a clinical-stage biopharmaceutical company. It focuses on discovering, acquiring, developing, and commercializing therapeutics in the disease areas of immunology, inflammation, and oncology. The company pipeline products include Seralutinib, which address the cellular overgrowth, fibrosis, and vascular remodeling which underlie PAH (pulmonary arterial hypertension); GB004, for the treatment of inflammatory bowel disease, including ulcerative colitis and Crohn's disease; GB1275, for the treatment of oncology indications; and GB001, for the treatment of moderate-to-severe eosinophilic asthma.

Previous Close:

$0.7017

Open:

$0.71

24h Volume:

517.43K

Relative Volume:

0.57

Market Cap:

$158.19M

Revenue:

Net Income/Loss:

$-179.82M

P/E Ratio:

-0.3159

EPS:

-2.21

Net Cash Flow:

$-159.16M

1W Performance:

+0.36%

1M Performance:

-23.65%

6M Performance:

+19.52%

1Y Performance:

-3.00%

1-Day Range:

$0.6944

$0.7299

1-Week Range:

$0.6901

$0.74

52-Week Range:

$0.4993

$1.60

Gossamer Bio Inc Stock (GOSS) Company Profile

Name

Gossamer Bio Inc

Sector

Healthcare (1180)

Industry

Biotechnology (675)

Phone

(858) 922-0718

Address

3013 SCIENCE PARK, SAN DIEGO, CA

Employee

135

Twitter

@GossamerBio

Next Earnings Date

2024-11-07

Latest SEC Filings

GOSS's Discussions on Twitter

Compare GOSS with other stocks

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
GOSS Gossamer Bio Inc	0.6981	158.19M	0	-179.82M	-159.16M	-1.33
VRTX Vertex Pharmaceuticals Inc	468.13	120.56B	10.63B	-479.80M	-1.35B	-1.99
REGN Regeneron Pharmaceuticals Inc	750.22	82.44B	13.85B	4.65B	3.32B	40.41
ARGX Argen X Se Adr	616.55	36.87B	1.86B	-40.29M	-1.28B	-0.85
ALNY Alnylam Pharmaceuticals Inc	253.07	32.64B	2.09B	-332.26M	16.06M	-2.62
BNTX Biontech Se Adr	118.39	28.38B	3.30B	-501.07M	1.03B	-2.1146

Gossamer Bio Inc Stock (GOSS) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Jun-25-24	Initiated	Oppenheimer	Outperform
Apr-05-24	Resumed	Wedbush	Outperform
Jul-27-23	Downgrade	UBS	Buy → Neutral
Mar-07-23	Downgrade	Raymond James	Outperform → Mkt Perform
Mar-01-23	Initiated	Guggenheim	Neutral
Dec-07-22	Downgrade	Barclays	Overweight → Equal Weight
Dec-07-22	Downgrade	JP Morgan	Neutral → Underweight
Dec-07-22	Downgrade	SMBC Nikko	Outperform → Neutral
Oct-20-22	Initiated	Goldman	Buy
Sep-21-22	Initiated	JP Morgan	Neutral
Sep-19-22	Initiated	Wedbush	Outperform
Apr-18-22	Initiated	Raymond James	Outperform
Apr-06-22	Initiated	UBS	Buy
Jan-10-22	Upgrade	SMBC Nikko	Neutral → Outperform
Nov-09-21	Resumed	Cantor Fitzgerald	Overweight
Sep-21-21	Resumed	Piper Sandler	Overweight
Jun-29-20	Initiated	H.C. Wainwright	Buy
Apr-22-20	Initiated	Piper Sandler	Overweight
Feb-27-20	Initiated	Barclays	Overweight
Dec-03-19	Resumed	BofA/Merrill	Buy
Oct-30-19	Initiated	Berenberg	Buy
Mar-05-19	Initiated	Barclays	Overweight
Mar-05-19	Initiated	BofA/Merrill	Buy
Mar-05-19	Initiated	Evercore ISI	Outperform
Mar-05-19	Initiated	SVB Leerink	Outperform

View All

Gossamer Bio Inc Stock (GOSS) Latest News

Nov 29, 2024

Gossamer Bio: Q3 Earnings Snapshot - Marketscreener.com

Nov 29, 2024

Nov 26, 2024

Adicet Bio Inc (NASDAQ: ACET) – Analysts’ Revisions Point To Positive Sentiment - Stocks Register

Nov 26, 2024

GSA Capital Partners LLP Invests $67,000 in Gossamer Bio, Inc. (NASDAQ:GOSS) - Defense World

Nov 26, 2024

Nov 25, 2024